Hyperfine, Inc. (HYPR) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Hyperfine, Inc. is a health technology company developing the Swoop® Portable MR Imaging System, an AI-powered, ultra-low-field (ULF) magnetic resonance device for brain imaging. The company operates as a single segment focused on the production, supply, and commercialization of the Swoop system. Key recent milestones include FDA 510(k) clearance in May 2025 for the next-generation Swoop system powered by Optive AI™ software, which improves image quality and acquisition times.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $3.44 million | $3.64 million | $8.27 million | $10.57 million |
| Gross Margin | $1.85 million (53.8%) | $1.91 million (52.4%) | $4.06 million (49.1%) | $5.07 million (47.9%) |
| Net Loss | $(11.02) million | $(10.33) million | $(29.66) million | $(30.33) million |
| Operating Cash Flow | N/A | N/A | $(22.74) million | $(30.41) million |
| Cash & Equivalents | $21.56 million | $37.65 million (Dec 2024) | $21.56 million | $37.65 million (Dec 2024) |
| Warrant Liabilities | $3.50 million | $0 | $3.50 million | $0 |
Note: Revenue declined YTD primarily due to a decrease in units sold (22 units YTD 2025 vs. 39 units YTD 2024), partially offset by an increase in average selling price.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 5.7% in Q3 and 21.8% YTD compared to 2024. Device sales dropped 24.9% YTD due to lower unit volume.
- Expense Reduction: Operating expenses decreased 16.3% in Q3 and 10.8% YTD. Research and Development (R&D) expenses fell 31.0% in Q3 and 21.7% YTD, driven by lower headcount and consulting costs.
- Warrant Liability Impact: A new line item, "Change in Fair Value of Warrant Liabilities," resulted in a non-cash loss of $2.3 million in Q3 and $0.6 million YTD, stemming from a February 2025 registered direct offering. This significantly impacted the net loss compared to the prior year.
- Liquidity: Cash and cash equivalents decreased from $37.6 million at year-end 2024 to $21.6 million at September 30, 2025, reflecting a net cash burn of $15.6 million over the nine-month period.
Guidance, Outlook, and Risks
- Capital Raise: Subsequent to the reporting period (October 2025), the company closed an underwritten public offering raising approximately $18.4 million in net proceeds. Management expects existing cash plus these proceeds to fund operations for at least the next 12 months.
- Product Strategy: The company is expanding commercialization beyond critical care into emergency departments and neurology clinics, supported by the launch of the next-generation Swoop system with Optive AI.
- Risks: The company has a history of losses and an accumulated deficit of $324.1 million. Continued negative operating cash flows and the need for additional financing pose risks to the going concern status if revenue growth does not accelerate. The company relies on a single-source manufacturer, creating supply chain vulnerability.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $18.4 million raised in October 2025 against the current burn rate to confirm the 12-month liquidity outlook.
- Unit Sales vs. ASP: Monitor the trend of unit sales volume versus Average Selling Price (ASP) to determine if revenue growth is driven by pricing power or volume adoption.
- Warrant Liability Volatility: Assess the impact of future stock price fluctuations on the fair value of warrant liabilities, which can create significant non-cash volatility in net loss.
- Customer Concentration: Review the concentration of revenue from top customers (four customers represented >10% of Q3 revenue) and the stability of these contracts.
- Regulatory Expansion: Track the commercial uptake of the Optive AI software in international markets (EU, UK, Canada, Australia) following recent CE Mark and UKCA approvals.